C-Reactive Protein and White Blood Cell Count in Cardiogenic Shock

This study examines the prognostic impact of C-reactive protein (CRP) and white blood cell (WBC) counts in patients with cardiogenic shock (CS). Data regarding the prognostic impact of inflammatory biomarkers in CS are scarce. All consecutive patients with CS from 2019 to 2021 admitted to a cardiac intensive care unit (ICU) were included at one institution. Laboratory measurements were retrieved from the day of admission (i.e., day 1), as well as days 2, 3, 4, and 8. The primary endpoint was 30-day all-cause mortality. Statistical analyses included univariate t-tests, Spearman’s correlations, C-statistics, Kaplan–Meier, and Cox regression analyses. From a total of 240 consecutive patients admitted with CS, 55% died within 30 days. CRP levels on days 3 to 8 were associated with reliable discrimination for 30-day all-cause mortality (area under the curve (AUC): 0.623–0.754), whereas CRP on day 1 was not (AUC = 0.514). In line, CRP > 100 mg/L on day 3 (56% vs. 37%; log-rank p = 0.023; HR = 1.702; 95% CI 1.060–2.735; p = 0.028) and especially a CRP increase of at least 200% from days 1 to day 3 (51% vs. 35%; log-rank p = 0.040; HR = 1.720; 95% CI 1.006–2.943; p = 0.048) were associated with an increased risk of all-cause mortality. Furthermore, WBC on day 1 discriminated 30-day all-cause mortality (AUC = 0.605; p = 0.005) with an increased risk of all-cause mortality in patients admitted with WBC > 10 × 106/mL (59% vs. 40%; log-rank p = 0.036; HR = 1.643; 95% CI 1.010–2.671; p = 0.045). In conclusion, WBC count on admission as well as CRP levels during the course of ICU treatment were associated with 30-day all-cause mortality. Specifically, an increase of CRP levels by at least 200% from day 1 to day 3 during the course of ICU treatment was associated with an increased risk of 30-day all-cause mortality. The present study is one of the first to describe the prognostic value of inflammatory biomarkers in consecutive all-comer CS patients treated at a cardiac ICU.

[1]  H. Thiele,et al.  Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial , 2022, Journal of clinical medicine.

[2]  T. Bertsch,et al.  Cardiac Troponin I Reveals Diagnostic and Prognostic Superiority to Aminoterminal Pro-B-Type Natriuretic Peptide in Sepsis and Septic Shock , 2022, Journal of clinical medicine.

[3]  J. Lassus,et al.  Biomarkers in cardiogenic shock. , 2022, Advances in clinical chemistry.

[4]  Sunil V. Rao,et al.  Cardiogenic Shock After Acute Myocardial Infarction: A Review. , 2021, JAMA.

[5]  Yuzhou Xue,et al.  Leukocyte and its Subtypes as Predictors of Short-Term Outcome in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Cohort Study , 2021, Shock.

[6]  I. König,et al.  Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. , 2021, The New England journal of medicine.

[7]  M. Bahloul,et al.  The value of sepsis biomarkers and their kinetics in the prognosis of septic shock due to bacterial infections , 2021, Anaesthesiology intensive therapy.

[8]  P. Kirchhof,et al.  Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation , 2020, Circulation.

[9]  P. Kirchhof,et al.  Left Ventricular Unloading is Associated with Lower Mortality in Cardiogenic Shock Patients Treated with Veno-Arterial Extracorporeal Membrane Oxygenation: Results From An International, Multicenter Cohort Study. , 2020, Circulation.

[10]  A. Mebazaa,et al.  Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock - Insights from the CardShock study. , 2020, International journal of cardiology.

[11]  C. Granger,et al.  Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology , 2020, European heart journal. Acute cardiovascular care.

[12]  S. Nah,et al.  Time course response of inflammatory markers in pediatric appendicitis , 2020, Pediatric Surgery International.

[13]  L. Bang,et al.  Admission Leukocyte Count is Associated with Late Cardiogenic Shock Development and All-Cause 30-Day Mortality in Patients with St-Elevation Myocardial Infarction. , 2020, Shock.

[14]  H. Daida,et al.  Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure , 2019, Heart and Vessels.

[15]  M. Shao,et al.  Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial , 2019, JAMA cardiology.

[16]  H. Thiele,et al.  One‐Year Outcomes after PCI Strategies in Cardiogenic Shock , 2018, The New England journal of medicine.

[17]  J. Pell,et al.  Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[18]  N. Hagiwara,et al.  Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. , 2018, The American journal of cardiology.

[19]  J. Ashworth,et al.  Role of C-Reactive Protein at Sites of Inflammation and Infection , 2018, Front. Immunol..

[20]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[21]  S. Ostrowski,et al.  Shock induced endotheliopathy (SHINE) in acute critical illness - a unifying pathophysiologic mechanism , 2017, Critical Care.

[22]  Marco Cosentino,et al.  Adrenergic regulation of innate immunity: a review , 2015, Front. Pharmacol..

[23]  T. Iba,et al.  Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis , 2015, Journal of immunology research.

[24]  Adila Elobeid,et al.  Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway. , 2014, Cytokine.

[25]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[26]  L. Smeeth,et al.  Ancestry as a Determinant of Mean Population C-Reactive Protein Values: Implications for Cardiovascular Risk Prediction , 2010, Circulation. Cardiovascular genetics.

[27]  J. Born,et al.  Selective Mobilization of Cytotoxic Leukocytes by Epinephrine , 2009, The Journal of Immunology.

[28]  N. Sucu,et al.  Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. , 2009, International heart journal.

[29]  Børge G Nordestgaard,et al.  Genetically elevated C-reactive protein and ischemic vascular disease. , 2008, The New England journal of medicine.

[30]  Judith S. Hochman,et al.  Cardiogenic Shock: Current Concepts and Improving Outcomes , 2008, Circulation.

[31]  A. Branzi,et al.  Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. , 2007, European heart journal.

[32]  O. Morel,et al.  Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. , 2006, American heart journal.

[33]  N. Lamblin,et al.  High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. , 2005, European heart journal.

[34]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[35]  B. Howard,et al.  C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes: The Strong Heart Study , 2005, Circulation.

[36]  M. Meisner,et al.  Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction , 2004, Critical care.

[37]  C. Mold,et al.  C-reactive protein , 2004, Immunologic research.

[38]  J. Deeks,et al.  Studies on the immediate and delayed leucocytosis elicited by brief (30-min) strenuous exercise , 2004, European Journal of Applied Physiology and Occupational Physiology.

[39]  E. Soppi,et al.  Effect of cardiopulmonary resuscitation-induced stress on cell-mediated immunity , 2004, Intensive Care Medicine.

[40]  J. Hochman,et al.  Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. , 2003, Circulation.

[41]  P. Póvoa,et al.  C-reactive protein: a valuable marker of sepsis , 2002, Intensive Care Medicine.

[42]  D W Brown,et al.  White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. , 2001, Journal of clinical epidemiology.

[43]  R. Mortensen.  C-reactive protein, inflammation, and innate immunity , 2001, Immunologic research.

[44]  E. Braunwald,et al.  Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy , 2000, Circulation.

[45]  H. Tomoda,et al.  Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. , 2000, American heart journal.

[46]  H. S,et al.  Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock , 2000 .

[47]  J. Olshaker,et al.  The C-reactive protein. , 1999, The Journal of emergency medicine.

[48]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[49]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[50]  R. Shephard,et al.  Stress Hormones and the Immunological Responses to Heat and Exercise , 1998, International journal of sports medicine.

[51]  M. Schedlowski,et al.  Catecholamine-Induced Leukocytosis: Early Observations, Current Research, and Future Directions , 1996, Brain, Behavior, and Immunity.

[52]  R. Telford,et al.  The response of leukocyte subsets and plasma hormones to interval exercise. , 1993, Medicine and science in sports and exercise.

[53]  R. Gougeon,et al.  Circulating mononuclear cell numbers and function during intense exercise and recovery. , 1991, Journal of applied physiology.

[54]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[55]  B. Muller,et al.  Early time course of the acute phase protein response in man. , 1983, Journal of clinical pathology.